中國將95種腫瘤、免疫和血液類藥物和200種配方零售價降低17%

《華爾街日報》

BEIJING—China set new price restrictions for some cancer and
blood-related drugs, as the country's leaders attempt to overhaul the
health-care system and reduce costs.

Retail-price cuts averaging
17% will take effect Oct. 8 for 95 oncology, immune-system and
blood-related drugs and 200 formulations, the National Development and
Reform Commission, China's main economic planning agency, said on its
website Tuesday.

中國發展和改革委員會週二在其網站上公佈將95種腫瘤、免疫和血液類藥物和200種配方的零售價降低17%。中國85%的死亡由慢性疾病如癌症引起。中國對製藥公司的價格限制有望在今年覆蓋到800種藥物。